Cargando…

A patient-driven clinicogenomic partnership for metastatic prostate cancer

Molecular profiling studies have enabled discoveries for metastatic prostate cancer (MPC) but have predominantly occurred in academic medical institutions and involved non-representative patient populations. We established the Metastatic Prostate Cancer Project (MPCproject, mpcproject.org), a patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Crowdis, Jett, Balch, Sara, Sterlin, Lauren, Thomas, Beena S., Camp, Sabrina Y., Dunphy, Michael, Anastasio, Elana, Shah, Shahrayz, Damon, Alyssa L., Ramos, Rafael, Sosa, Delia M., Small, Ilan K., Tomson, Brett N., Nguyen, Colleen M., McGillicuddy, Mary, Chastain, Parker S., He, Meng Xiao, Cheung, Alexander T.M., Wankowicz, Stephanie, Tewari, Alok K., Kim, Dewey, AlDubayan, Saud H., Dowdye, Ayanah, Zola, Benjamin, Nowak, Joel, Manarite, Jan, Gunn, Idola Henry, Olson, Bryce, Lander, Eric S., Painter, Corrie A., Wagle, Nikhil, Van Allen, Eliezer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518748/
https://www.ncbi.nlm.nih.gov/pubmed/36177448
http://dx.doi.org/10.1016/j.xgen.2022.100169
Descripción
Sumario:Molecular profiling studies have enabled discoveries for metastatic prostate cancer (MPC) but have predominantly occurred in academic medical institutions and involved non-representative patient populations. We established the Metastatic Prostate Cancer Project (MPCproject, mpcproject.org), a patient-partnered initiative to involve patients with MPC living anywhere in the US and Canada in molecular research. Here, we present results from our partnership with the first 706 MPCproject participants. While 41% of patient partners live in rural, physician-shortage, or medically underserved areas, the MPCproject has not yet achieved racial diversity, a disparity that demands new initiatives detailed herein. Among molecular data from 333 patient partners (572 samples), exome sequencing of 63 tumor and 19 cell-free DNA (cfDNA) samples recapitulated known findings in MPC, while inexpensive ultra-low-coverage sequencing of 318 cfDNA samples revealed clinically relevant AR amplifications. This study illustrates the power of a growing, longitudinal partnership with patients to generate a more representative understanding of MPC.